Dr. Chari on Challenges in Sequencing Agents for Multiple Myeloma
Ajai Chari, MD
Ajai Chari, MD, associate professor, Mount Sinai Hospital, discusses challenges in sequencing agents for patients with multiple myeloma.
According to Chari, the use of daratumumab (Darzalex) induction therapy and ixazomib (Ninlaro) in the maintenance setting are making patients refractory to a different drug class.
Many researchers are investigating how quickly chimeric antigen receptor (CAR) T-cell therapy can be given to patients based on the risk value, explains Chari.